BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

462 related articles for article (PubMed ID: 34131114)

  • 1. USP35, regulated by estrogen and AKT, promotes breast tumorigenesis by stabilizing and enhancing transcriptional activity of estrogen receptor α.
    Cao J; Wu D; Wu G; Wang Y; Ren T; Wang Y; Lv Y; Sun W; Wang J; Qian C; He L; Yang K; Li H; Gu H
    Cell Death Dis; 2021 Jun; 12(6):619. PubMed ID: 34131114
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PFKFB3 regulates breast cancer tumorigenesis and Fulvestrant sensitivity by affecting ERα stability.
    Jia W; Wu Q; Shen M; Yu X; An S; Zhao L; Huang G; Liu J
    Cell Signal; 2024 Jul; 119():111184. PubMed ID: 38640982
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The ERα-miR-575-p27 feedback loop regulates tamoxifen sensitivity in ER-positive Breast Cancer.
    Liu SS; Li Y; Zhang H; Zhang D; Zhang XB; Wang X; Yu Y
    Theranostics; 2020; 10(23):10729-10742. PubMed ID: 32929377
    [No Abstract]   [Full Text] [Related]  

  • 4. AKT3 regulates ErbB2, ErbB3 and estrogen receptor α expression and contributes to endocrine therapy resistance of ErbB2(+) breast tumor cells from Balb-neuT mice.
    Grabinski N; Möllmann K; Milde-Langosch K; Müller V; Schumacher U; Brandt B; Pantel K; Jücker M
    Cell Signal; 2014 May; 26(5):1021-9. PubMed ID: 24463007
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The estrogen receptor-interacting protein HPIP increases estrogen-responsive gene expression through activation of MAPK and AKT.
    Wang X; Yang Z; Zhang H; Ding L; Li X; Zhu C; Zheng Y; Ye Q
    Biochim Biophys Acta; 2008 Jun; 1783(6):1220-8. PubMed ID: 18302941
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of FGFR1 with ERα Maintains Ligand-Independent ER Transcription and Mediates Resistance to Estrogen Deprivation in ER
    Formisano L; Stauffer KM; Young CD; Bhola NE; Guerrero-Zotano AL; Jansen VM; Estrada MM; Hutchinson KE; Giltnane JM; Schwarz LJ; Lu Y; Balko JM; Deas O; Cairo S; Judde JG; Mayer IA; Sanders M; Dugger TC; Bianco R; Stricker T; Arteaga CL
    Clin Cancer Res; 2017 Oct; 23(20):6138-6150. PubMed ID: 28751448
    [No Abstract]   [Full Text] [Related]  

  • 7. AR collaborates with ERα in aromatase inhibitor-resistant breast cancer.
    Rechoum Y; Rovito D; Iacopetta D; Barone I; Andò S; Weigel NL; O'Malley BW; Brown PH; Fuqua SA
    Breast Cancer Res Treat; 2014 Oct; 147(3):473-85. PubMed ID: 25178514
    [TBL] [Abstract][Full Text] [Related]  

  • 8. O-GlcNAcylation-inducing treatments inhibit estrogen receptor α expression and confer resistance to 4-OH-tamoxifen in human breast cancer-derived MCF-7 cells.
    Kanwal S; Fardini Y; Pagesy P; N'tumba-Byn T; Pierre-Eugène C; Masson E; Hampe C; Issad T
    PLoS One; 2013; 8(7):e69150. PubMed ID: 23935944
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transcriptional regulation of vascular endothelial growth factor by estradiol and tamoxifen in breast cancer cells: a complex interplay between estrogen receptors alpha and beta.
    Buteau-Lozano H; Ancelin M; Lardeux B; Milanini J; Perrot-Applanat M
    Cancer Res; 2002 Sep; 62(17):4977-84. PubMed ID: 12208749
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human phosphatidylethanolamine-binding protein 4 promotes transactivation of estrogen receptor alpha (ERalpha) in human cancer cells by inhibiting proteasome-dependent ERalpha degradation via association with Src.
    Liu H; Qiu J; Li N; Chen T; Cao X
    J Biol Chem; 2010 Jul; 285(29):21934-42. PubMed ID: 20460377
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Maintenance of S-nitrosothiol homeostasis plays an important role in growth suppression of estrogen receptor-positive breast tumors.
    Cañas A; López-Sánchez LM; Valverde-Estepa A; Hernández V; Fuentes E; Muñoz-Castañeda JR; López-Pedrera C; De La Haba-Rodríguez JR; Aranda E; Rodríguez-Ariza A
    Breast Cancer Res; 2012 Dec; 14(6):R153. PubMed ID: 23216744
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long Non-Coding RNA H19 Acts as an Estrogen Receptor Modulator that is Required for Endocrine Therapy Resistance in ER+ Breast Cancer Cells.
    Basak P; Chatterjee S; Bhat V; Su A; Jin H; Lee-Wing V; Liu Q; Hu P; Murphy LC; Raouf A
    Cell Physiol Biochem; 2018; 51(4):1518-1532. PubMed ID: 30497079
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MEK5/ERK5 signaling suppresses estrogen receptor expression and promotes hormone-independent tumorigenesis.
    Antoon JW; Martin EC; Lai R; Salvo VA; Tang Y; Nitzchke AM; Elliott S; Nam SY; Xiong W; Rhodes LV; Collins-Burow B; David O; Wang G; Shan B; Beckman BS; Nephew KP; Burow ME
    PLoS One; 2013; 8(8):e69291. PubMed ID: 23950888
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CSNK1G2 differently sensitizes tamoxifen-induced decrease in PI3K/AKT/mTOR/S6K and ERK signaling according to the estrogen receptor existence in breast cancer cells.
    Nguyen Hoang AT; Hoe KL; Lee SJ
    PLoS One; 2021; 16(4):e0246264. PubMed ID: 33861751
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Keratinocyte growth factor (KGF) regulates estrogen receptor-alpha (ER-alpha) expression and cell apoptosis via phosphatidylinositol 3-kinase (PI3K)/Akt pathway in human breast cancer cells.
    Chang HL; Sugimoto Y; Liu S; Wang LS; Huang YW; Ye W; Lin YC
    Anticancer Res; 2009 Aug; 29(8):3195-205. PubMed ID: 19661335
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Menin, a product of the MENI gene, binds to estrogen receptor to enhance its activity in breast cancer cells: possibility of a novel predictive factor for tamoxifen resistance.
    Imachi H; Murao K; Dobashi H; Bhuyan MM; Cao X; Kontani K; Niki S; Murazawa C; Nakajima H; Kohno N; Yamashita H; Iwase H; Hayashi S; Ishida T; Yamauchi A
    Breast Cancer Res Treat; 2010 Jul; 122(2):395-407. PubMed ID: 19847644
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MiR-301a-3p Suppresses Estrogen Signaling by Directly Inhibiting ESR1 in ERα Positive Breast Cancer.
    Lettlova S; Brynychova V; Blecha J; Vrana D; Vondrusova M; Soucek P; Truksa J
    Cell Physiol Biochem; 2018; 46(6):2601-2615. PubMed ID: 29763890
    [TBL] [Abstract][Full Text] [Related]  

  • 18. AKT Antagonist AZD5363 Influences Estrogen Receptor Function in Endocrine-Resistant Breast Cancer and Synergizes with Fulvestrant (ICI182780) In Vivo.
    Ribas R; Pancholi S; Guest SK; Marangoni E; Gao Q; Thuleau A; Simigdala N; Polanska UM; Campbell H; Rani A; Liccardi G; Johnston S; Davies BR; Dowsett M; Martin LA
    Mol Cancer Ther; 2015 Sep; 14(9):2035-48. PubMed ID: 26116361
    [TBL] [Abstract][Full Text] [Related]  

  • 19. OTUD7B stabilizes estrogen receptor α and promotes breast cancer cell proliferation.
    Tang J; Wu Z; Tian Z; Chen W; Wu G
    Cell Death Dis; 2021 May; 12(6):534. PubMed ID: 34035221
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulation of ERalpha-mediated transcription of Bcl-2 by PI3K-AKT crosstalk: implications for breast cancer cell survival.
    Bratton MR; Duong BN; Elliott S; Weldon CB; Beckman BS; McLachlan JA; Burow ME
    Int J Oncol; 2010 Sep; 37(3):541-50. PubMed ID: 20664923
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.